SEC Form 4 · accession 0000899243-18-014478
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian McVeigh
Officer — Chief Business Officer
Period of report
May 29, 2018
Accepted (ET)
May 30, 2018 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.46 | May 29, 2018 | A | 225,000 | A | — | May 29, 2028 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F125% of this option vests on May 29, 2019 and the remainder vests in equal monthly installments thereafter over a 3-year period. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control pursuant to the terms of the reporting person's Severance and Change in Control Agreement dated as of May 29, 2018.